Indian Pharmas Seen Ripe For Domestic Consolidation
This article was originally published in PharmAsia News
Some pharmaceutical industry experts in India see recent tries to acquire Orchid Pharmaceuticals and Dabur Pharma as indicative of a new consolidation move in India. In the past, the industry has spurned consolidation on grounds it has 20,000 members able to market in India. But experts see a dwindling share of that market by Indian companies driving a merger move by many. One industry leader said consolidation would improve efficiency and increase production capacity while preventing facility duplication. (Click here for more
You may also be interested in...
The company has no development programs left in its R&D pipeline and will focus entirely on the commercialization of IBS drug Linzess while seeking late-stage assets from external sources.
The documents issued by the US agency on 29 September set slightly different accuracy standards, reflecting the increased fragility of hospital patients.
The US FDA commissioner published a blog post commending and highlighting the work device center staff have done during the pandemic to speed tests and devices to market to save lives.